organization · Reporting owner
QVT Financial Investment Cayman Ltd.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sio Gene Therapies Inc.
Report date July 10, 2019 · Filed July 12, 2019
Jointly reported with QVT Associates GP LLC
Section 16 reporting ended · disclosed 2019-07-12. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Urovant Sciences Ltd.
Report date July 10, 2019 · Filed July 12, 2019
Jointly reported with QVT Associates GP LLC
Section 16 reporting ended · disclosed 2019-07-12. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 19, 2019 Filed Jun 19, 2019 18:52 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 4,957 | $8.17 | $40,495.22 |
DisclosureSEC source: 0000899243-19-017480 · doc4.xml · nonDerivative · entry 3 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · (see fn5) Disclosed balance after: 22,860,013 F1 · shares: The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the "Exchange Act") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. F4 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.00 to $8.27, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4. F5 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,860,013 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| June 18, 2019 Filed Jun 19, 2019 18:52 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 6,706 | $8.21 | $55,060.95 |
DisclosureSEC source: 0000899243-19-017480 · doc4.xml · nonDerivative · entry 2 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · (see fn5) Disclosed balance after: 22,855,056 F1 · shares: The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the "Exchange Act") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. F3 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.09 to $8.29, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4. F5 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,860,013 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 18:52 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 6,541 | $8.53 | $55,824.82 |
DisclosureSEC source: 0000899243-19-017480 · doc4.xml · nonDerivative · entry 1 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · (see fn5) Disclosed balance after: 22,848,350 F1 · shares: The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the "Exchange Act") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. F2 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.11 to $8.70, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. ("Urovant"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F5 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,860,013 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| June 14, 2019 Filed Jun 14, 2019 18:16 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 7,144 | $7.91 | $56,514.04 |
DisclosureSEC source: 0000899243-19-017094 · doc4.xml · nonDerivative · entry 3 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · (see fn5) Disclosed balance after: 22,841,809 F1 · shares: The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the "Exchange Act") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. F4 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.65 to $8.00, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4. F5 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,841,809 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 18:16 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 7,367 | $7.95 | $58,542.60 |
DisclosureSEC source: 0000899243-19-017094 · doc4.xml · nonDerivative · entry 2 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · (see fn5) Disclosed balance after: 22,834,665 F1 · shares: The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the "Exchange Act") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. F3 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.67 to $8.39, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4. F5 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,841,809 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 18:16 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 7,500 | $8.30 | $62,244.00 |
DisclosureSEC source: 0000899243-19-017094 · doc4.xml · nonDerivative · entry 1 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · (see fn5) Disclosed balance after: 22,827,298 F1 · shares: The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the "Exchange Act") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. F2 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.16 to $8.77, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. ("Urovant"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F5 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,841,809 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| June 11, 2019 Filed Jun 11, 2019 19:05 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 7,189 | $8.58 | $61,693.84 |
DisclosureSEC source: 0000899243-19-016511 · doc4.xml · nonDerivative · entry 3 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 22,819,798 F1 · shares: The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the "Exchange Act") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. F4 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.41 to $8.75, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4. F5 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,819,798 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 19:05 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 7,500 | $8.35 | $62,594.25 |
DisclosureSEC source: 0000899243-19-016511 · doc4.xml · nonDerivative · entry 2 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 22,812,609 F1 · shares: The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the "Exchange Act") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. F3 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.89 to $8.68, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4. F5 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,819,798 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 19:05 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 6,649 | $7.97 | $52,959.29 |
DisclosureSEC source: 0000899243-19-016511 · doc4.xml · nonDerivative · entry 1 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 22,805,109 F1 · shares: The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the "Exchange Act") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. F2 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.73 to $8.10, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. ("Urovant"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F5 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,819,798 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| June 06, 2019 Filed Jun 6, 2019 20:57 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 7,082 | $8.00 | $56,621.30 |
DisclosureSEC source: 0000899243-19-015910 · doc4.xml · nonDerivative · entry 3 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 22,798,460 F1 · shares: The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the "Exchange Act") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. F4 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.73 to $8.57, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4. F5 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,798,460 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 20:57 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 6,540 | $8.02 | $52,418.10 |
DisclosureSEC source: 0000899243-19-015910 · doc4.xml · nonDerivative · entry 2 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 22,791,378 F1 · shares: The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the "Exchange Act") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. F3 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.68 to $8.33, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4. F5 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,798,460 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 20:57 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 7,500 | $7.59 | $56,910.75 |
DisclosureSEC source: 0000899243-19-015910 · doc4.xml · nonDerivative · entry 1 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 22,784,838 F1 · shares: The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the "Exchange Act") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. F2 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.42 to $7.71, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. ("Urovant"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F5 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,798,460 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| June 03, 2019 Filed Jun 3, 2019 18:18 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 5,424 | $7.71 | $41,814.70 |
DisclosureSEC source: 0000899243-19-015402 · doc4.xml · nonDerivative · entry 4 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,777,338 F1 · shares: The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the "Exchange Act") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. F5 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.64 to $7.74, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4. F6 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,777,338 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 18:18 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 5,071 | $7.70 | $39,042.14 |
DisclosureSEC source: 0000899243-19-015402 · doc4.xml · nonDerivative · entry 3 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,771,914 F1 · shares: The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the "Exchange Act") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. F4 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.41 to $7.84, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4. F6 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,777,338 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 18:18 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 300 | $8.91 | $2,671.98 |
DisclosureSEC source: 0000899243-19-015402 · doc4.xml · nonDerivative · entry 2 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,766,843 F1 · shares: The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the "Exchange Act") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. F3 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.71 to $9.03, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4. F6 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,777,338 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 18:18 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 6,951 | $7.97 | $55,417.54 |
DisclosureSEC source: 0000899243-19-015402 · doc4.xml · nonDerivative · entry 1 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,766,543 F1 · shares: The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934 (the "Exchange Act") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. F2 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.70 to $8.70, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. ("Urovant"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F6 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,777,338 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| May 29, 2019 Filed May 29, 2019 18:05 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 6,882 | $7.55 | $51,983.19 |
DisclosureSEC source: 0000899243-19-015062 · doc4.xml · nonDerivative · entry 3 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · (see fn5) Disclosed balance after: 22,759,592 F1 · shares: The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. F4 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.40 to $7.69, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4. F5 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,759,592 Common Shares held by Roivant because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein Read SEC document |
| May 28, 2019 Filed May 29, 2019 18:05 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 3,807 | $7.68 | $29,244.61 |
DisclosureSEC source: 0000899243-19-015062 · doc4.xml · nonDerivative · entry 2 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · (see fn5) Disclosed balance after: 22,752,710 F1 · shares: The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. F3 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.65 to $7.70, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4. F5 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,759,592 Common Shares held by Roivant because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein Read SEC document |
| May 24, 2019 Filed May 29, 2019 18:05 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 3,796 | $7.70 | $29,233.38 |
DisclosureSEC source: 0000899243-19-015062 · doc4.xml · nonDerivative · entry 1 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · (see fn5) Disclosed balance after: 22,748,903 F1 · shares: The transaction was a series of open market purchases made by Roivant Sciences Ltd. ("Roivant") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. F2 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.66 to $7.74, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. ("Urovant"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F5 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,759,592 Common Shares held by Roivant because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein Read SEC document |
| May 23, 2019 Filed May 23, 2019 18:26 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 4,802 | $7.76 | $37,252.00 |
DisclosureSEC source: 0000899243-19-014556 · doc4.xml · nonDerivative · entry 3 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · (see fn6) Disclosed balance after: 22,745,107 F3 · shares: The transaction was a series of open market purchases made under a trading plan established pursuant to Rule 10b5-1 under the Exchange Act and in accordance with the safe harbor of Rule 10b-18. F5 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.645 to $7.98, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4. F6 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,745,107 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| May 22, 2019 Filed May 23, 2019 18:26 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 5,033 | $8.06 | $40,557.93 |
DisclosureSEC source: 0000899243-19-014556 · doc4.xml · nonDerivative · entry 2 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · (see fn6) Disclosed balance after: 22,740,305 F3 · shares: The transaction was a series of open market purchases made under a trading plan established pursuant to Rule 10b5-1 under the Exchange Act and in accordance with the safe harbor of Rule 10b-18. F4 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.825 to $8.43, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4. F6 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,745,107 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| May 21, 2019 Filed May 23, 2019 18:26 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 9,995 | $8.52 | $85,108.42 |
DisclosureSEC source: 0000899243-19-014556 · doc4.xml · nonDerivative · entry 1 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · (see fn6) Disclosed balance after: 22,735,272 F1 · shares: The transaction was a series of open market purchases made in accordance with the safe harbor of Rule 10b-18 ("Rule 10b-18") under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.31 to $8.69, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. ("Urovant"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F6 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,745,107 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| May 20, 2019 Filed May 20, 2019 18:32 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 1,715 | $8.39 | $14,383.19 |
DisclosureSEC source: 0000899243-19-014214 · doc4.xml · nonDerivative · entry 4 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · (see fn6) Disclosed balance after: 22,725,277 F1 · shares: Each transaction was a series of open market purchases made in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.36 to $8.47, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4. F6 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,725,277 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| May 20, 2019 Filed May 20, 2019 18:32 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 8,285 | $7.98 | $66,141.64 |
DisclosureSEC source: 0000899243-19-014214 · doc4.xml · nonDerivative · entry 3 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · (see fn6) Disclosed balance after: 22,723,562 F1 · shares: Each transaction was a series of open market purchases made in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.35 to $8.35, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (4) to this Form 4. F6 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,725,277 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| May 17, 2019 Filed May 20, 2019 18:32 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 6,200 | $7.36 | $45,641.30 |
DisclosureSEC source: 0000899243-19-014214 · doc4.xml · nonDerivative · entry 2 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · (see fn6) Disclosed balance after: 22,715,277 F1 · shares: Each transaction was a series of open market purchases made in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.03 to $7.85, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4. F6 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,725,277 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| May 16, 2019 Filed May 20, 2019 18:32 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | PurchaseCommon Shares, par value $0.000037453 per share | 5,408 | $6.79 | $36,718.16 |
DisclosureSEC source: 0000899243-19-014214 · doc4.xml · nonDerivative · entry 1 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · (see fn6) Disclosed balance after: 22,709,077 F1 · shares: Each transaction was a series of open market purchases made in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $6.70 to $6.93, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. ("Urovant"), any security holder of Urovant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. F6 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 22,725,277 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws. The filing of this statement shall not be deemed an admission that QVT is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. QVT expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Read SEC document |
| March 18, 2019 Filed Mar 19, 2019 17:15 UTC | Sio Gene Therapies Inc. AXON · Entity 130622 | PurchaseCommon Shares, $0.00001 par value per share | 6,666,667 | $1.50 | $10,000,000.50 |
DisclosureSEC source: 0000899243-19-008356 · doc4.xml · nonDerivative · entry 1 QVT Associates GP LLC · CIK 0001290166 · 10% owner QVT Financial Investment Cayman Ltd. · CIK 0001771138 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · see fn Disclosed balance after: 105,952,381 F1 · ownership.nature: QVT Financial LP, its general partner, QVT Financial GP LLC, QVT Financial Investment Cayman Ltd. and QVT Associates GP LLC, the general partner of certain funds managed by QVT Financial LP (collectively, "QVT"), may be deemed to have beneficial ownership over the 105,952,381 Common Shares held by Roivant Sciences Ltd. ("Roivant") because, as shareholders of Roivant, QVT may be deemed to have dispositive power and, therefore, beneficial ownership, over the Common Shares held by Roivant by virtue of governance arrangements in Roivant's bye-laws, namely, the appointment of one or more independent directors (within the meaning of that term under Roivant's bye-laws) to Roivant's board of directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.